HC Wainwright restated their buy rating on shares of Palatin Technologies (NYSEAMERICAN:PTN – Free Report) in a research report sent to investors on Thursday morning, Benzinga reports. They currently have a $17.00 price target on the biopharmaceutical company’s stock.
Palatin Technologies Stock Down 0.9 %
PTN stock opened at $1.09 on Thursday. The company has a market capitalization of $21.31 million, a price-to-earnings ratio of -0.52 and a beta of 0.99. Palatin Technologies has a 12 month low of $0.68 and a 12 month high of $5.65.
Palatin Technologies (NYSEAMERICAN:PTN – Get Free Report) last posted its quarterly earnings data on Tuesday, October 1st. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter. On average, equities research analysts predict that Palatin Technologies will post -2.03 EPS for the current fiscal year.
Hedge Funds Weigh In On Palatin Technologies
Palatin Technologies Company Profile
Palatin Technologies, Inc, a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder.
Recommended Stories
- Five stocks we like better than Palatin Technologies
- 3 Fintech Stocks With Good 2021 Prospects
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- 3 REITs to Buy and Hold for the Long Term
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What is a SEC Filing?
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with MarketBeat.com's FREE daily email newsletter.